Obesity Research Peptide

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity

Published Time: 2021-09-08

About us

Who we are

• Mission and values
• History
• Leadership
• Awards

Impact and progress

• Frontiers' impact
• Our annual reports
• Thought leadership

Publishing model

• How we publish
• Open access
• Peer review
• Research integrity
• Research Topics
• FAIR² Data Management
• Fee policy

Services

• Societies
• National consortia
• Institutional partnerships
• Collaborators

More from Frontiers

• Frontiers Forum
• Frontiers Planet Prize
• Press office
• Sustainability
• Career opportunities
• Contact us

Sections

• Adrenal Endocrinology
• Bone Research
• Cancer Endocrinology
• Cardiovascular Endocrinology
• Cellular Endocrinology
• Clinical Diabetes
• Developmental Endocrinology
• Diabetes: Molecular Mechanisms
• Endocrinology of Aging
• Experimental Endocrinology
• Gut Endocrinology
• Molecular and Structural Endocrinology
• Neuroendocrine Science
• Obesity
• Pediatric Endocrinology
• Pituitary Endocrinology
• Renal Endocrinology
• Reproduction
• Systems Endocrinology
• Thyroid Endocrinology
• Translational and Clinical Endocrinology

About journal

Scope

• Field chief editors
• Mission & scope
• Facts
• Journal sections
• Open access statement
• Copyright statement
• Quality

For authors

• Why submit?
• Article types
• Author guidelines
• Editor guidelines
• Publishing fees
• Submission checklist
• Contact editorial office